Kazazian Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Kazazian Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.31M	Buy	332,635 +255,853	+333%	+$2.07M	1.76%	18
2019 Q2	$1.14M	Sell	76,782 -20,038	-21%	-$362K	1.35%	24
2019 Q1	$2.4M	Sell	96,820 -9,522	-9%	-$239K	3.34%	10
2018 Q4	$1.91M	Buy	106,342 +2,226	+2%	+$45.5K	2.58%	13
2018 Q3	$3.06M	Buy	104,116 +33,618	+48%	+$1.3M	2.86%	11
2018 Q2	$3.21M	Buy	70,498 +33,969	+93%	+$1.65M	2.94%	10
2018 Q1	$1.93M	Buy	36,529 +17,012	+87%	+$993K	2.02%	12
2017 Q4	$1.33M	Buy	19,517 +2,024	+12%	+$142K	1.36%	20
2017 Q3	$1.44M	Buy	17,493 +6,229	+55%	+$494K	1.76%	16
2017 Q2	$1.05M	Buy	+11,264	New	+$689K	1.6%	16
2016 Q2	–	Sell	-14,666	Closed	-$282K	–	64
2016 Q1	$282K	Buy	+14,666	New	+$310K	0.54%	25

Other funds holding CLVS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Kazazian Asset Management's CLVS Position: Q3 2019 in Review

Kazazian Asset Management increased its Clovis Oncology, Inc. (CLVS) stake by 333% in Q3 2019, buying an estimated $2.07M and bringing the position to 332,635 shares worth $1.31M. The position accounts for 1.76% of the portfolio, ranked #18.

Kazazian Asset Management first reported a position in CLVS in Q1 2016 and has held it in 11 quarters since. The position peaked at $3.21M in Q2 2018. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

Kazazian Asset Management held 332,635 shares of Clovis Oncology, Inc. worth $1.31M as of Q3 2019.
Kazazian Asset Management bought 255,853 Clovis Oncology, Inc. shares in Q3 2019, an estimated $2.07M.
Clovis Oncology, Inc. made up 1.76% of Kazazian Asset Management's portfolio in Q3 2019, its #18 holding.
Kazazian Asset Management first reported a position in Clovis Oncology, Inc. in Q1 2016 and has held it in 11 quarters since.
Kazazian Asset Management's Clovis Oncology, Inc. position peaked at $3.21M in Q2 2018.
153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Kazazian Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.